VEXAS syndrome registry with blood sample collection
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study creates a national registry for people with VEXAS syndrome to track the disease and collect blood samples for research. Joining helps doctors learn more about VEXAS so they can better diagnose and treat it in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed (or your doctor strongly suspects) VEXAS syndrome
- You are 18 years or older
- You can understand the study and sign a consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks for people age 50+ with unexplained inflammation or blood problems like anemia or low platelets. It aims to better identify a rare condition called VEXAS syndrome, which causes these symptoms.
This study tests an investigational drug called arumakimig (MAS825) in people with VEXAS, a rare genetic condition that causes inflammation. The trial checks if the drug helps control symptoms and improve quality of life.
This trial tests whether a new drug called momelotinib can help treat VEXAS syndrome, a rare genetic inflammatory condition. The study will see if it can reduce inflammation and allow patients to use less steroid medication.
This study analyzes blood, bone marrow, and medical information from people with bone marrow failure syndromes (BMFS) and healthy volunteers to better understand these conditions and find new ways to help patients.
This trial tests a new drug called pacritinib for people with VEXAS syndrome, a rare autoinflammatory condition. The goal is to see if pacritinib can help control symptoms like rashes, joint pain, and low blood counts.
This study looks at how VEXAS syndrome affects your daily life and finances. It aims to understand the challenges you face so doctors can better support you.
Hear when a new VEXAS Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.